Recent Company News

• 01:45 AM ET Feb 05, 2026
  

  Santen Pharmaceutical reports Q3 core net income attributable ¥9.62B vs FactSet ¥9.52B [3 est, ¥9.04-10.43B] (¥1774.0000, 0)

• 10:20 PM ET Feb 04, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (393 total)

• 04:38 PM ET Jan 26, 2026
  

  UBS initiates 4151.JP, 4503.JP, 4507.JP, others

• 10:18 PM ET Jan 13, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (372 total)

• 09:44 PM ET Jan 12, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (309 total)

• 12:37 PM ET Dec 22, 2025
  

  Santen obtains manufacturing and marketing approval in Japan for UPNEEQ mini ophthalmic solution 0.1%, a treatment for acquired Blepharoptosis (¥1637.5000, 0)

• 03:30 AM ET Dec 05, 2025
  

  Japan's MHLW lists Santen Pharmaceutical and Bayer's aflibercept intraocular injection kit 40 mg/mL in National Health Insurance Drug Price List (¥1551.0000, 0)

• 01:52 AM ET Nov 06, 2025
  

  Santen Pharmaceutical completes ¥31.9B buyback (¥1499.5000, 0)

• 01:46 AM ET Nov 06, 2025
  

  Santen Pharmaceutical reports Q2 core net income ¥9.84B vs FactSet ¥7.78B (¥1499.5000, 0)

• 09:40 AM ET Nov 05, 2025
  

  Santen announces UK approves Ryjunea to slow progression of childhood myopia (¥1518.5000, 0)